Stabilized compositions of radionuclides and uses thereof

A liquid radiopharmaceutical composition comprising:

• (a) 225Ac-DOTA-TATE or a pharmaceutically acceptable salt thereof, wherein the 225Ac-DOTA-TATE or the pharmaceutically acceptable salt thereof is present in the radiopharmaceutical composition at a concentration equivalent to 10 mCi/L to 30 mCi/L;
• (b) sodium ascorbate, wherein the sodium ascorbate is present in the radiopharmaceutical composition at a concentration of 40 mM to 250 mM;
• (c) diethylenetriamine pentaacetate (DTPA);
• and
• (d) an aqueous vehicle, wherein the aqueous vehicle is a saline solution;
• wherein the radiopharmaceutical composition is a solution, and
• wherein the radiopharmaceutical composition retains at least 90% of the 225Ac content as 225Ac-DOTA-TATE or the pharmaceutically acceptable salt thereof after 120 hours at about 20° C. to about 25° C.